Recent Posts
News•Feb 28, 2026
Humana Offers Scholarships for Xavier Ochsner College of Medicine to Boost Physician Workforce
Humana has launched a $3 million endowment to provide full‑tuition scholarships for incoming students at Xavier Ochsner College of Medicine (XOCOM). The fund targets high‑achieving candidates facing financial hardship and requires recipients to practice in Louisiana, focusing on primary care, internal medicine, or maternal health. The initiative responds to an AAMC‑projected national shortfall of 86,000 physicians by 2036, with Louisiana expected to rank third in shortages by 2030. By bolstering the physician pipeline, Humana aims to improve health‑care access across the state.
By AJMC (The American Journal of Managed Care)
News•Feb 28, 2026
In China, Phase 2 Study of Relma-Cel in R/R MCL Finds Durable Responses
A phase‑2 trial of relmacabtagene autoleucel (relma‑cel), a CD19‑directed CAR‑T therapy, enrolled 59 Chinese patients with relapsed/refractory mantle‑cell lymphoma after BTK‑inhibitor failure. The study reported a 71.2% overall response rate and a 59.3% complete response rate, with median time to...
By AJMC (The American Journal of Managed Care)
News•Feb 28, 2026
Environmental Factors Affect Community Participation Among Individuals With MS
A mixed‑methods study of 505 people with multiple sclerosis (MS) found that personal factors dominate community‑participation outcomes, but environmental factors still contributed an additional 11 % to satisfaction and GPS‑tracked activity. Financial resources, social support and neighborhood safety were linked to...
By AJMC (The American Journal of Managed Care)
News•Feb 28, 2026
Pregnancy Biomarkers Reveal Long-Term Cardiovascular Risk in Women
A Danish registry‑linked cohort linked pregnancy biobanking with long‑term health records, showing that third‑trimester high‑sensitivity cardiac troponin I (hs‑cTnI) and soluble fms‑like tyrosine kinase‑1 (sFlt‑1) independently predict maternal cardiovascular disease (CVD) over a median 12‑year follow‑up. Adding week‑29 sFlt‑1 to...
By AJMC (The American Journal of Managed Care)
News•Feb 28, 2026
Recent Advances Raise Hopes of Better Addressing Richter Transformation
A new review synthesizes recent advances that clarify the biology of Richter transformation (RT), the aggressive lymphoma that develops in 2%‑10% of chronic lymphocytic leukemia (CLL) patients. The analysis confirms that 70%‑80% of RT cases are clonally related to the...
By AJMC (The American Journal of Managed Care)
News•Feb 28, 2026
Analysis Finds Efficiencies, Savings of Using a Single Bispecific for DLBCL and FL
A new analysis quantifies the operational and financial benefits of using Genmab’s epcoritamab, a dual‑indication bispecific antibody, for both relapsed/refractory diffuse large B‑cell lymphoma (DLBCL) and follicular lymphoma (FL). In a community‑practice model of 100 patients, the study projects 3,110...
By AJMC (The American Journal of Managed Care)
News•Feb 28, 2026
Alcohol-Associated Liver Disease Conveys Greater Cirrhosis Risk Than Metabolic Disease
A new VA study of 1.5 million veterans shows alcohol‑associated liver disease (ALD) carries the highest cirrhosis incidence (0.66 per 100 person‑years), outpacing metabolic dysfunction‑associated steatotic liver disease (MASLD) and metabolic‑and‑alcohol‑associated liver disease (MetALD). MASLD patients with obesity and diabetes face...
By AJMC (The American Journal of Managed Care)
News•Feb 28, 2026
Advanced CKD Linked With Cognitive Impairment
A new JAMA Network Open analysis of 5,607 chronic kidney disease (CKD) patients found that higher urinary protein‑to‑creatinine ratios (UPCR) and lower estimated glomerular filtration rates (eGFR) independently raise the risk of cognitive deficits, especially in attention, processing speed, and...
By AJMC (The American Journal of Managed Care)
News•Feb 28, 2026
Mixed Immune Signature Identified in Chronic Hand Eczema
A phase‑2b trial enrolling 94 adults with chronic hand eczema (CHE) without etiologic pre‑selection uncovered a mixed immune signature spanning type 2, type 3 and type 1 pathways. Dupilumab, an IL‑4Rα antagonist, delivered a 59.8% mean improvement in modified Total Lesion Symptom Score...
By AJMC (The American Journal of Managed Care)
News•Feb 27, 2026
5 Things to Know About the Emerging Measles Outbreaks in the US
The United States recorded 2,280 measles cases in 2025, the highest tally since 1991, and early 2026 has already seen 910 additional cases, concentrated in South Carolina, Utah and Florida. Low MMR vaccination coverage—just 64% for a single dose—has been...
By AJMC (The American Journal of Managed Care)
News•Feb 26, 2026
FAQ: How Long COVID Is Defined, Diagnosed, and Managed in 2026
Long COVID remains clinically fragmented as the CDC, WHO and the National Academy of Sciences each use slightly different definitions, creating gaps in diagnosis and treatment equity. High‑risk groups—women, older adults, smokers and those with obesity—continue to experience disproportionate symptom...
By AJMC (The American Journal of Managed Care)
News•Feb 26, 2026
FDA Grants Accelerated Approval to Zongertinib for HER2-Mutant NSCLC
The FDA granted accelerated approval to zongertinib (Hernexeos) for adults with unresectable or metastatic non‑squamous NSCLC that carry activating HER2 TKD mutations, extending its use to treatment‑naive patients. The decision rests on the Beamion LUNG‑1 trial, which reported a 76%...
By AJMC (The American Journal of Managed Care)
News•Feb 26, 2026
Machine Learning May Enable Earlier Detection of CKD Risk Factors
A recent study demonstrates that a machine‑learning pipeline combining advanced feature selection with ensemble classifiers markedly improves chronic kidney disease (CKD) risk prediction. Gradient‑boosting models achieved the highest performance, reaching 98% accuracy, 99% recall and an AUC of 0.99, while...
By AJMC (The American Journal of Managed Care)
News•Feb 25, 2026
Prospective Study in High-Risk Individuals Supports Primary Prevention Trials in MS
A prospective analysis of 1,903 first‑degree relatives of multiple sclerosis (MS) patients found an incidence of 211 cases per 100,000 per year—about 100‑fold higher than the general population—and a median conversion time of two years, with diagnosis typically at age...
By AJMC (The American Journal of Managed Care)
News•Feb 25, 2026
CAB+RPV LA Is Versatile, Preferred in Treatment-Naive Patients
Long‑acting cabotegravir/rilpivirine (CAB+RPV LA) demonstrated strong virologic control and high patient preference in both treatment‑naïve and treatment‑experienced cohorts presented at CROI 2026. In the VOLITION trial, 85% of ART‑naïve adults switched early from DTG/3TC to a q2‑month injectable, achieving 95% overall suppression...
By AJMC (The American Journal of Managed Care)